4D Molecular Therapeutics Highlights Pipeline Progress at Leerink Conference

Company provides updates on late-stage ophthalmology program, cystic fibrosis development, and cash runway

Mar. 17, 2026 at 9:26am

Got story updates? Submit your updates here. ›

Executives from 4D Molecular Therapeutics (NASDAQ:FDMT) provided updates on the company's late-stage ophthalmology program, commercialization planning, cystic fibrosis development efforts, and cash runway during an appearance at the 2026 Leerink Partners Global Healthcare Conference in Miami. The company highlighted progress with its lead gene therapy candidate 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), as well as its inhaled gene therapy 4D-710 for cystic fibrosis.

Why it matters

4D Molecular Therapeutics is a clinical-stage biotech company focused on developing targeted gene therapies for rare diseases. The updates on its late-stage ophthalmology and cystic fibrosis programs, as well as its financial position, provide insight into the company's progress and future plans as it advances its pipeline.

The details

For its lead ophthalmology program, 4D-150, the company is conducting two Phase III trials in wet AMD and DME. Executives highlighted the rapid enrollment, particularly in the treatment-naïve population, as a positive sign for future commercial demand. The company has also seen promising results in earlier clinical work, with an approximately 80-90% reduction in treatment burden for patients. In cystic fibrosis, 4D discussed its inhaled gene therapy candidate 4D-710, which has demonstrated robust and reproducible transgene expression in Phase I studies. The company is now enrolling a Phase II trial and plans to provide a program update in the second half of 2026. Financially, 4D reported having over $510 million in cash as of the end of 2025, providing a runway into the second half of 2028 that extends beyond expected data readouts for its key ophthalmology programs.

  • 4FRONT-1 wet AMD data expected in the first half of 2027.
  • 4FRONT-2 wet AMD data expected in the second half of 2027.
  • Planned initiation of DME trial in the third quarter of 2026.

The players

4D Molecular Therapeutics

A clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases.

David Kirn

Founder and CEO of 4D Molecular Therapeutics.

Chris Simms

Chief Commercial and Business Officer of 4D Molecular Therapeutics.

Kristian Humer

Chief Financial Officer of 4D Molecular Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.